This is a competitive renewal for Penn's P30 NIDDK Center on Molecular Therapy for Cystic Fibrosis and Genetic Diseases which has been in place since 1993. At the last renewal we shifted our strategy from a focus on clinical trials to vector discovery and distribution with an increased emphasis on immunology and animal models. This has had the desired result of substantially fueling a robust pipeline of promising preclinical programs that are entering clinical trials with better technology and an enhanced understanding of vector biology necessary for clinical success. With encouragement from NIDDK, we expanded access to our Cores to investigators outside of Penn to establish important strategic collaborations. During this cycle of the grant, Vector Core services increased from 576 in year 11 of the grant to 1458 projected for the current year (year 15). The substantial expansion of gene and cell therapy research associated with our Center is due in large part to the availability of new AAV and lentiviral technology discovered at Penn and distributed through our Vector Core. An important aspect of this expansion has been in the area of immunology that has emerged as a major impediment to success. The Center has aggressively recruited the participation of scientists interested in applied immunology and genetic vaccines to focus on issues relevant to gene and cell therapy. The current research base is substantial and strong across all areas relevant to the Center. Current total annual direct costs of grants awarded to Center Participants has been organized into the following three areas: Genetic Diseases, Stem Cells and Gene Transfer - $49 mil;Cystic Fibrosis - $8.6 mil;and Immunology and Vaccines -$14.9 mil. The Pjlot Grant program remains strong and has been useful in supporting young investigators and encouraging the participation of new investigators. Important recruitments at Penn have provided the opportunity to enhance leadership of the Center's Cores. This application requests support for Pilot Grants as well as the following Cores: Vector, Immunology, Cell Morphology and Animal Models.

Public Health Relevance

The Gene Therapy Program at Penn provides leadership and support to a diverse array of both Penn and external investigators in the area of cell and gene therapy for cystic fibrosis and genetic diseases. The program advises Center Participants with accumulated expertise as well as provided cutting-edge viral-vector technology and immune response analysis through the Vector and Immunology Cores - Such interactions have fueled the progression of two important gene therapies into clinical trials in the last funding period and will continue to do so in the future periods.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK047757-20S1
Application #
8851233
Study Section
Special Emphasis Panel (ZDK1-GRB-1 (J2))
Program Officer
Eggerman, Thomas L
Project Start
1997-09-30
Project End
2015-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
20
Fiscal Year
2014
Total Cost
$807,759
Indirect Cost
$294,896
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Gurda, Brittney L; De Guilhem De Lataillade, Adrien; Bell, Peter et al. (2016) Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther 24:206-16
Ortved, Kyla; Wagner, Bettina; Calcedo, Roberto et al. (2015) Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint. Hum Gene Ther 26:161-71
Bissig-Choisat, Beatrice; Wang, Lili; Legras, Xavier et al. (2015) Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun 6:7339
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Calcedo, Roberto; Franco, Judith; Qin, Qiuyue et al. (2015) Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods 26:103-5
Baek, Jeong-In; Choi, Soo Young; Chacon-Heszele, Maria F et al. (2014) Expression of Drosophila forkhead transcription factors during kidney development. Biochem Biophys Res Commun 446:15-7
O'Neill, S M; Hinkle, C; Chen, S-J et al. (2014) Targeting adipose tissue via systemic gene therapy. Gene Ther 21:653-61
Huang, Liwei; Xiao, An; Wecker, Andrea et al. (2014) A possible zebrafish model of polycystic kidney disease: knockdown of wnt5a causes cysts in zebrafish kidneys. J Vis Exp :
Huang, Liwei; Xiao, An; Choi, Soo Young et al. (2014) Wnt5a is necessary for normal kidney development in zebrafish and mice. Nephron Exp Nephrol 128:80-8
Adam, Virginie S; Crosariol, Marco; Kumar, Sachin et al. (2014) Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol 21:1528-33

Showing the most recent 10 out of 222 publications